Among patients with obesity and migraine, weight loss is associated with reduction of migraine frequency, pain severity, and attack duration and disability.
Researchers analyzed the relationship between migraines and psoriasis in the general US population, using data obtained from the 2003-2004 National Health and Nutrition Examination Survey (NHANES).
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ofatumumab (Novartis) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
There is no evidence for an association between cerebral β-amyloid deposition, a marker of Alzheimer disease, and intracranial atherosclerotic plaque or stenosis.
Cohort study data from 2018 to 2019 suggest poor compliance with the US Food and Drug Administration reporting requirements for clinical trial sponsors.
A network of gut bacteria species may be associated with host genetic factors that increase susceptibility to multiple sclerosis.
More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.
The onset of hyperlipidemia may occur earlier in patients with multiple sclerosis.
Patients who have been diagnosed with and treated for multiple sclerosis (MS) have an increased risk for any type of infection, with the highest risk being for renal tract infections.
Researchers sought to find any genetic variants associated with migraine or MS that could be identified from genome-wide association studies.
Fatigue, anemia, pain, and sleep disorders form part of the prodrome in MS.
Home telehealth may be a feasible and safe option for veterans with multiple sclerosis who have difficulty accessing services from the VA or community services.
Patients with vs without multiple sclerosis were found to be at increased risk for several cardiac events.
Roughly half of patients with pediatric-onset multiple sclerosis (MS) who transition to adult clinics experience worsened clinical disability.
Using newer disease-modifying therapies for the initial treatment of pediatric multiple sclerosis may be more effective than injectables at controlling disease activity.
The researchers concluded that patients with both MS and depression experience worsening in neurological function, relapses, and lesions activity after 1 year compared with patients without depression.
Researchers of the study assessed the sensitivity and specificity of the STOP-Bang tool in patients with MS.
In this study presented at ACTRIMS Forum 2020, researchers evaluated the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of EHP-101, an oral formulation of VCE-004.8.
Pediatric patients with multiple sclerosis (MS) and a high relative abundance of Pasteurellales or Enterobacteriales in their gut microbiota have a lower relapse risk.
A diagnostic test for fragile X syndrome (FXS) has been cleared by the Food and Drug Administration.